CAB Payments Holdings Limited a market lender to business to business (B2B) cross-border payments and foreign exchange, specialising in emerging markets intends to join the Premium Segment of the Main Market. The Group announced revenues of £41.3m for the three months ended 31 March 2023 with YTD adjusted EBITDA margin at 64%. The Offer is expected to comprise a secondary sell-down of existing ordinary shares by Merlin Midco Limited (a wholly owned subsidiary of Helios Investors III, L.P. and Helios Investors III (A), L.P.)
WE Soda, the world’s largest producer of natural soda ash, more commonly known in the UK as sodium carbonate or washing soda, announces that it is considering listing on the Premium Segment of the Main Market. WE Soda, an extractor of soda ash in Turkey and the US, is a subsidiary of Ciner Group, an industrial and media conglomerate. It is a high-margin business and last year it reported adjusted operating profits of $892m on revenues of $1.77 bn. The Offer would be wholly comprised of ordinary shares to be sold by the existing shareholder. Separately from and in addition to the Offer, the Company is also considering making an exempt public offer of Shares to retail investors in the UK through the PrimaryBid platform. The value of Shares sold will not exceed EUR8m equivalent (approximately £6.95m).
Cambridge Cognition Holdings 101.5p £35.3m (COG.L)
The developer and marketer of digital solutions to assess brain health, announces it has won a £2m contract for a pivotal cancer therapy trial. The Company will provide its proprietary cognitive assessments (CANTAB®) as an exploratory endpoint with revenue from the contract expected to be recognised over the next 5 years. Supported by the Company's experienced clinical project management team, CANTAB® will be deployed in 9 countries and in 11 languages to accurately assess cognition across 70 trial sites.
Driver Group 32p £16.7m (DRV.L)
The provide of consultancy services to the engineering and construction industries announces its interim results for the six months ended 31 March 2023. Revenue was slightly down to £24.2m (2022: £24.4m) which is attributable to the restructured Middle East and Asia Pacific regions. Gross profit margin at 26% (2022: 24%), a £0.5m increase to £6.3m (2022: £5.9m). Profit before tax increased to £0.5m (2022: £0.1m) and net cash increased to £5.3m (2022: £3.7m). Revenues in the Europe and Americas (EuAm) region increased to £19.1m (2022: £17.4m) with revenues in the Middle East down to £3.7m (2022: £5.4m) and revenues in APAC down to £1.4m (2022: £1.7m). This is in line with the company’s strategy of EuAm being the central business hub. Driver Group's business in EuAm continues to trade profitably, and post-restructure, the Middle East are expected to contribute a profit for the current financial year with APAC being well placed to improve further during FY24 as a consequence of work coming out of Korea.
Hellenic Dynamics 0.115p £14.5m (HELD.L)
The specialist cultivator and supplier of tetrahydrocannabinol (THC) dominant strains of medical cannabis flowers, announces it has signed a Memorandum of Understanding (MoU) with Deutsche Medizinalcannabis GmbH, which trades as Demecan Holding, for the cultivation and supply of medical cannabis flowers. Demecan is the only licensed independent German company that covers the entire value chain for medical cannabis from cultivation through processing to distribution. This MoU represents the first commercial agreement for the company under the expanded contract cultivation strategy. Under the MoU, Hellenic will grow and supply medical cannabis flowers from Demecan provided cultivars, in an indoor cultivation area capable of producing circa 1,200 kg of medical cannabis flowers per annum under Good Agricultural and Collection Practice (GACP). Demecan will then process the delivered flowers in its own EU-GMP facilities for onward sale. Hellenic Dynamics is also in discussions with a number of other licensed European distributors, who have their own GMP processing facilities for similar POD agreements.
Pennant International Group 36.5p £13.4m (PEN.L)
The IPS software and services company, provides a business update, with a number of new contract wins. The company has secured a contract on an Australian defence programme, to supply software solutions and technical services worth AUD$5.2m over 5 years, representing the first sale of Pennant's new GenS software, which will be fully launched to market in early 2024. Pennant have also secured an upgrade on an existing Australian contract to provide specialist facilities and services worth AUD$1.2m over 5 years; a £250k perpetual software licence to a European defence department; and a contract for technical railway mapping services in the UK, worth circa £130k this year.
Rockfire Resources 0.33p £6.1m (ROCK.L)
The base metal, gold and critical mineral exploration company, announces that the Company's fourth drill hole, as part of its geotechnical drilling programme at the Company's Molaoi zinc deposit in Greece, continues to encounter strong zinc continuity. Two lodes have been intersected reaffirming that multiple lodes are continuous at Molaoi. An upper lode of 2.37m @ 6.0% Zn occurs from 107m, as well as 0.8% Pb and 31.3g/t Ag and a lower lode of 2.3m @ 5.3% Zn occurs from 110m, as well as 1.3% Pb and 13.6g/t Ag. Zinc/lead/silver mineralisation continues to be encountered in the projected positions as identified from the historical drilling by the Greek Government.
Roquefort Therapeutics* 6.75p £8.7m (ROQ.L)
The biotech company focused on developing first in class medicines in the high value and high growth oncology market announces the successful completion of in vitro studies for the Company's anti-cancer mRNA therapeutic in breast and liver cancer. The studies demonstrated a statistically significant reduction in both proliferation (cancer growth) and migration. The Roquefort Therapeutics team and collaborators at the University of New South Wales have accelerated development of the MDK mRNA Program and successfully demonstrated its cancer killing ability in validated in vitro models of breast and liver cancer. The mRNA cancer market is a highly attractive new field of medicine (~$31bn, 7.8% CAGR) and is led by Pfizer, Moderna and BioNTech. Roquefort Therapeutics is well positioned in this field, with four mRNA sequences that uniquely target Midkine. These results, while early, validate ROQ’s strategy that demonstrating a significant reduction in both proliferation and migration are an early proxy for metastasis. In parallel, the company’s intellectual property portfolio has been enhanced through updated patent filing.
Tertiary Minerals 0.12p £2.4m (TYM.L)
The mineral deposit exploration and development announces that it's 96% owned Zambian subsidiary, Tertiary Minerals (Zambia) Limited, has applied for, and had approved for grant, a new mineral exploration licence at Mupala in Zambia. The Mupala Project mineral exploration Licence application 32139-HQ-LEL is located 12 km west of the Company's Mukai Project and has been approved for grant by the Mining Licensing Committee of the Ministry of Mines and Minerals Development. The licence application is located adjacent to and immediately east of the Anglo American/Arc Minerals joint venture licence block where Anglo American has the right to earn a 70% interest through expenditure of $88.5m and is for an initial period of four years from the date of grant.
Trinity Exploration & Production 82p £31.5m (TRIN.L)
The independent E&P company focused on Trinidad and Tobago, announces that it has been advised by the Government of Trinidad and Tobago Ministry of Energy and Energy Industries (MEEI) that Trinity's application for the Buenos Ayres block offered in the 2022 Onshore and Nearshore Competitive Bid Round has been successful. The MEEI has invited Trinity to enter into discussions for the grant of an Exploration and Production (Public Petroleum Rights) Licence for the Buenos Ayres Block. Trinity expects to be Operator of the Buenos Ayres block with an 85% interest. Heritage Petroleum Company Limited, the state-owned oil company, will have a 15% working interest (carried by Trinity through the exploration phase).
Vianet Group 85.5p £25.2m (VNET.L)
The international provider of actionable data and business insight through devices connected to its Internet of Things platform (IOT), announces its unaudited results for the year ended 31 March 2023 and a reinstated proposed final dividend of 0.5p per share. Revenue increased 6.7% to £14.11m (FY2022: £13.22m) and recurring revenues remained stable at 89% (FY2022: 88%) increasing by £1.19m to £12.56m. The Company reported a profit before tax of £0.45m after previously reporting a FY2022 loss of £0.17m. The Group is on track to deliver strong earnings growth across its two divisions and maximise the opportunities in new verticals for the financial year ending March 2024 and beyond.
Yourgene Health 0.25p £7.9m (YGEN.L)
An international molecular diagnostic group, announces the conditional divestment of its Taiwanese subsidiary, Yourgene Health Taiwan Co Ltd, to INEX Innovate Pte Ltd, a Singapore based molecular diagnostics company focused on women's and fetal health for proceeds of up to $4m USD (c.£3.2m). The Divestment is conditional upon INEX being granted Taiwanese Government approval. Terms of the Divestment include: US$1m payable on the closing date, and $1m payable as a lump sum or via ad hoc instalments within two years of the closing date (carrying interest at 7% above the Bank of England base rate), and up to US$2m potential earnout subject to the achievement of certain profit related milestones, over the next two calendar years post completion. The Loan Agreement is secured against the shares of the subsidiary being sold such that failure to pay will result in ownership returning to Yourgene with no obligation to return previously received funds.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
